LEXINGTON, Mass., Nov. 28, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate at Citi's 2018 Global Healthcare Conference on Wednesday, December 5, 2018 at the Lotte New York Palace Hotel in New York, NY.
About Aldeyra Therapeutics
Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal inflammation, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-participate-at-citis-2018-global-healthcare-conference-300756510.html
SOURCE Aldeyra Therapeutics, Inc.